These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1339 related articles for article (PubMed ID: 15356789)

  • 1. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline.
    Nikolic-Djokic D; Essajee S; Rigaud M; Kaul A; Chandwani S; Hoover W; Lawrence R; Pollack H; Sitnitskaya Y; Hagmann S; Jean-Philippe P; Chen SH; Radding J; Krasinski K; Borkowsky W
    J Infect Dis; 2002 Feb; 185(3):290-8. PubMed ID: 11807710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART.
    Chiappini E; Galli L; Tovo PA; Gabiano C; Lisi C; Gattinara GC; Esposito S; Viganò A; Giaquinto C; Rosso R; Guarino A; de Martino M
    AIDS; 2007 Jul; 21(12):1607-15. PubMed ID: 17630556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
    Nesheim SR; Kapogiannis BG; Soe MM; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2007 Jul; 120(1):100-9. PubMed ID: 17606567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children.
    Resino S; Resino R; Maria Bellón J; Micheloud D; Gutiérrez MD; de José MI; Ramos JT; Fontelos PM; Ciria L; Muñoz-Fernández MA;
    Clin Infect Dis; 2006 Jul; 43(2):243-52. PubMed ID: 16779753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006).
    Guillén S; García San Miguel L; Resino S; Bellón JM; González I; Jiménez de Ory S; Muñoz-Fernández MA; Navarro ML; Gurbindo MD; de José MI; Mellado MJ; Martín-Fontelos P; Gonzalez-Tomé MI; Martinez J; Beceiro J; Roa MA; Ramos JT;
    HIV Med; 2010 Apr; 11(4):245-52. PubMed ID: 20050937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications.
    Glikman D; Walsh L; Valkenburg J; Mangat PD; Marcinak JF
    Pediatrics; 2007 May; 119(5):e1142-8. PubMed ID: 17452493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospitalization trends among children and youths with perinatal human immunodeficiency virus infection, 1990-2002.
    Bertolli J; Hsu HW; Sukalac T; Williamson J; Peters V; Frederick T; Rakusan TA; Ortiz I; Melville SK; Dominguez K;
    Pediatr Infect Dis J; 2006 Jul; 25(7):628-33. PubMed ID: 16804434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.